GUARDO, DANIELA
 Distribuzione geografica
Continente #
EU - Europa 966
AS - Asia 197
NA - Nord America 88
SA - Sud America 17
AF - Africa 6
Totale 1.274
Nazione #
IT - Italia 926
SG - Singapore 83
US - Stati Uniti d'America 80
CN - Cina 58
VN - Vietnam 33
BR - Brasile 15
FR - Francia 12
FI - Finlandia 9
GB - Regno Unito 5
HK - Hong Kong 4
IN - India 4
BD - Bangladesh 3
CA - Canada 3
MX - Messico 3
NL - Olanda 3
ZA - Sudafrica 3
DE - Germania 2
ES - Italia 2
ID - Indonesia 2
JP - Giappone 2
TR - Turchia 2
AZ - Azerbaigian 1
BB - Barbados 1
CL - Cile 1
CY - Cipro 1
DK - Danimarca 1
EG - Egitto 1
IE - Irlanda 1
JM - Giamaica 1
KE - Kenya 1
KW - Kuwait 1
MD - Moldavia 1
NP - Nepal 1
PH - Filippine 1
PK - Pakistan 1
PL - Polonia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TZ - Tanzania 1
UA - Ucraina 1
VE - Venezuela 1
Totale 1.274
Città #
Genoa 460
Genova 266
Rapallo 99
Vado Ligure 83
Singapore 48
San Jose 26
Ashburn 22
Beijing 11
Hanoi 9
Ho Chi Minh City 9
Helsinki 8
Lauterbourg 8
Bordighera 4
Hong Kong 4
New York 4
Amsterdam 3
Catania 3
City of London 3
Council Bluffs 3
Mexico City 3
São Paulo 3
Biên Hòa 2
Dallas 2
Frankfurt am Main 2
Haiphong 2
Hyderabad 2
Los Angeles 2
Madrid 2
Marseille 2
Paris 2
Santa Clara 2
Seattle 2
Tianjin 2
Tokyo 2
Toronto 2
Acalanes Ridge 1
Angra dos Reis 1
Ankara 1
As Sālimīyah 1
Aurangabad 1
Baku 1
Bandung 1
Barquisimeto 1
Bertioga 1
Bratislava 1
Bridgetown 1
Buffalo 1
Cabo Frio 1
Cairo 1
Calamba 1
Chicago 1
Chisinau 1
Copenhagen 1
Cruz Alta 1
Dar es Salaam 1
Dois Irmãos 1
Dublin 1
Francisco Morato 1
Guarulhos 1
Haikou 1
Hazard 1
Hortolândia 1
Hưng Yên 1
Islamabad 1
Johannesburg 1
Kathu 1
Kharkiv 1
Lappeenranta 1
Ljubljana 1
London 1
Long An 1
Louisville 1
Molfetta 1
Montreal 1
Nairobi 1
Naples 1
New Delhi 1
Nicosia 1
Parambu 1
Poplar 1
Pretoria 1
Rio de Janeiro 1
Rome 1
Salt Lake City 1
Sidoarjo 1
Staten Island 1
Teresina 1
Traiguén 1
Vĩnh Tường 1
Vũng Tàu 1
Warsaw 1
Totale 1.163
Nome #
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 211
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 189
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 179
Underlying CTLA4 deficiency in a patient with juvenile idiopathic arthritis and autoimmune lymphoproliferative syndrome features successfully treated with abatacept - A case report 120
Genetic screening of children with marrow failure. The role of primary Immunodeficiencies 107
The challenge of early diagnosis of autoimmune lymphoproliferative syndrome in children with suspected autoinflammatory/autoimmune disorders 99
Good tolerability of high dose colistin-based therapy in patients with haematological malignancies 81
Targeted ngs yields plentiful ultra-rare variants in inborn errors of immunity patients 78
Infection risk of Mycophenolate Mofetil and Sirolimus treatments in patients with Autoimmune Cytopenias and Primary Immuno-Regulatory Disorders. 71
Hematopoietic stem cell transplantation for inborn errors of immunity: 30-year single-center experience 69
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 59
Chromosomal Deletion Involving ANKRD26 Leads to Expression of a Fusion Protein Responsible for ANKRD26-Related Thrombocytopenia 49
Totale 1.312
Categoria #
all - tutte 4.928
article - articoli 4.695
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.623


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202113 0 0 0 0 0 0 0 0 0 4 2 7
2021/202279 1 1 6 7 2 6 2 10 11 16 3 14
2022/2023121 11 16 2 10 18 14 0 2 15 8 21 4
2023/2024113 0 10 2 12 9 11 6 20 7 4 20 12
2024/2025288 7 14 6 19 22 25 36 69 18 14 32 26
2025/2026498 70 5 31 55 81 29 98 21 53 55 0 0
Totale 1.312